Xerion’s therapeutic development activities focus on cancer and autoimmune diseases. Each disease area is characterized by a significant market size and an unmet medical need for innovative therapies. Furthermore, cancer and autoimmune diseases are suitable indications for antibody-based therapies.

(Click on image for larger view).

By applying its core Xstream® technology to these therapeutic areas, Xerion has been able to turn information from diseased cells into druggable targets and fully human therapeutic antibodies.

For further details in pdf format, download : Xerion Non-confidential Project-Package